During a press conference at the American College of Cardiology’s (ACC) 65th Annual Scientific Session, Vericel Corp (NASDAQ:VCEL) presented the Phase 2b results of its ixCELL-DCM clinical study, which relates to ixmyelocel-T in patients with heart disorders.

Substantial reduction in adverse events

The company reported that its stem cell therapy substantially reduced the deaths and hospitalisation among those patients, who had progressed to advance stage of heat failure. Overall, the company noted that its therapy is effective in delaying the need of heart transplants in heart failure patients.

The study was aimed to provide a comparison in between the effectiveness of the company’s stem cell therapy and placebo. The study comprised of 109 patients, who had advanced ischemic heart failure and had found all the optimal medical and device therapies ineffective.

After one year of trial study, the results showed that Vericel’s therapy showed a 37% fall in adverse events versus placebo. These adverse events included death, heart-related hospitalisation and unplanned clinical visits stemming from heart failure.

Effective against placebo

The detailed report follows the company’s announcement last month when it had said the successful completion of its clinical study. Alongside presenting the results at the scientific meeting in Chicago, the company has also disclosed the results in the Lancet medical journal.

Patients treated with the company’s ixmyelocel-T therapy resulted in just two deaths when compared to 7 deaths in the placebo group. Similarly, 38% of the patients receiving the company’s therapy required hospitalisation against 47% in placebo group. Meanwhile, the study failed to meet the secondary goals of the trial, which included higher efficiency of heart pumping or six-minute walking distance.

Lead investigator and chief of cardiology at Cedars-Sinai Heart Institute, Dr. Timothy Henry, stated that the therapy should undergo larger trials to prove its ability to counter heart disorders. He cited the results as an extremely significant milestone for both the company and the patients.

The stock of Vericel Corp (NASDAQ:VCEL) bounced back by 4.57% to $3.72 during the previous trading session.

Previous articleGilead Sciences, Inc. (NASDAQ:GILD) Buys Stake In Nimbus Apollo To Gain Access To Metabolic Diorder Therapy
Next articleBaxalta Inc (NYSE:BXLT) Gets Japanese Ministry’s Approval To Market ADYNOVATE
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.